References

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update

10.1200/jco.18.01160 · 2019 · External reference

Advances in endocrine therapy for hormone receptor-positive advanced breast cancer

10.1007/s11912-023-01393-6 · 2023 · External reference

Overcoming endocrine resistance in breast cancer

10.1016/j.ccell.2020.03.009 · 2020 · External reference

Endocrine therapy combined with targeted therapy in hormone receptor-positive metastatic breast cancer

10.1097/cm9.0000000000000923 · 2020 · External reference

Cellular and humoral immunodeficiency in breast cancer patients resistant to hormone therapy

10.4149/neo_2014_013 · 2014 · External reference

Current landscape of immunotherapy in breast cancer: a review

10.1001/jamaoncol.2018.7147 · 2019 · External reference

Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion

10.1038/s41568-021-00339-z · 2021 · External reference

Antigen processing and immune regulation in the response to tumours

10.1111/imm.12675 · 2017 · External reference

Association of tamoxifen resistance and lipid reprogramming in breast cancer

10.1186/s12885-018-4757-z · 2018 · External reference

Correlation between serum lipid levels and endocrine resistance in patients with ER-positive breast cancer

10.1097/md.0000000000035048 · 2023 · External reference

Contradictory roles of lipid metabolism in immune response within the tumor microenvironment

10.1186/s13045-021-01200-4 · 2021 · External reference

Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages

10.15252/emmm.201910698 · 2019 · External reference

Ginsenoside Rh3 induces pyroptosis and ferroptosis through the Stat3/p53/NRF2 axis in colorectal cancer cells

10.3724/abbs.2023068 · 2023 · External reference

Ginsenoside Rh4 inhibits colorectal cancer cell proliferation by inducing ferroptosis via autophagy activation

10.1155/2022/6177553 · 2022 · External reference

The role of the tumor microenvironment in endocrine therapy resistance in hormone receptor-positive breast cancer

10.3389/fendo.2023.1261283 · 2023 · External reference

T cell dysfunction in cancer

10.1016/j.ccell.2018.03.012 · 2018 · External reference

T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment

10.1016/j.coi.2012.12.003 · 2013 · External reference

Molecular and cellular insights into T cell exhaustion

10.1038/nri3862 · 2015 · External reference

Immunotherapy in breast cancer: current status and future directions

10.1016/bs.acr.2019.03.006 · 2019 · External reference

Lipid droplets and cellular lipid metabolism

10.1146/annurev-biochem-061009-102430 · 2012 · External reference

Lipid metabolism

10.1101/cshperspect.a040576 · 2021 · External reference

Metabolic reprogramming in cancer: dysregulation of glucose, lipid, and amino acid pathways and therapeutic opportunities

10.1186/s43556-026-00427-2 · 2026 · External reference

Metabolic reprogramming in cancer: signaling pathways and therapeutic targets

10.1186/s12943-026-02582-0 · 2026 · External reference

The role of tumor metabolic reprogramming in tumor immunity

10.3390/ijms242417422 · 2023 · External reference

Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics

10.1186/s13045-023-01498-2 · 2023 · External reference

Lipid metabolism reprogramming in cancer: insights into tumor cells and immune cells within the tumor microenvironment

10.3390/biomedicines13081895 · 2025 · External reference

Lipid metabolism reprogramming shapes the immune landscape in the tumor microenvironment

10.1038/s41423-026-01411-0 · 2026 · External reference

Tumor lipid signatures are descriptive of acquisition of therapy resistance in an endocrine-related breast cancer mouse model

10.1021/acs.jproteome.3c00382 · 2024 · External reference

Lipid metabolism and breast cancer therapy: an integrative literature review

10.2147/bctt.s575419 · 2026 · External reference

The diversity and breadth of cancer cell fatty acid metabolism

10.1186/s40170-020-00237-2 · 2012 · External reference

Dysregulated lipid metabolism in cancer

10.4331/wjbc.v3.i8.167 · 2012 · External reference

Lipid metabolic reprograming: the unsung hero in breast cancer progression and tumor microenvironment

10.1186/s12943-025-02258-1 · 2025 · External reference

Lipid biology of breast cancer

10.1016/j.bbalip.2013.03.011 · 2013 · External reference

Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells

10.18632/oncotarget.2059 · 2014 · External reference

ATP citrate lyase: a central metabolic enzyme in cancer

10.1016/j.canlet.2019.12.010 · 2020 · External reference

Exogenous lipids promote the growth of breast cancer cells via CD36

10.3892/or.2017.5864 · 2017 · External reference

FABP4 in lipid metabolism and the tumor microenvironment: mechanisms and therapeutic potential

10.1186/s12944-025-02833-x · 2025 · External reference

Molecular mediators of metabolic reprogramming in cancer: mechanisms, regulatory networks, and therapeutic strategies

10.1111/imm.70045 · 2026 · External reference

Fatty acid trafficking between lipid droplets and mitochondria: an emerging perspective

10.7150/ijbs.105361 · 2025 · External reference

Lipid droplet and its implication in cancer progression

2020 · External reference

A prismatic view of the epigenetic-metabolic regulatory axis in breast cancer therapy resistance

10.1038/s41388-024-03054-9 · 2024 · External reference

Lipid metabolic reprogramming drives triglyceride storage and variable sensitivity to FASN inhibition in endocrine-resistant breast cancer cells

10.1186/s13058-025-01991-1 · 2025 · External reference

Metabolomic rewiring promotes endocrine therapy resistance in breast cancer

10.1158/0008-5472.can-23-0184 · 2024 · External reference

Low GPR81 in ER+ breast cancer cells drives tamoxifen resistance through inducing PPARα-mediated fatty acid oxidation

10.1016/j.lfs.2024.122763 · 2024 · External reference

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy-tolerant persister cells in ER+ breast cancer

10.1158/0008-5472.can-24-1204 · 2025 · External reference

Hormone receptor loss in breast cancer: molecular mechanisms, clinical settings, and therapeutic implications

10.3390/cells9122644 · 2020 · External reference

Mechanisms of endocrine resistance in hormone receptor-positive breast cancer

10.1007/978-3-031-33602-7_9 · 2023 · External reference

Endocrine-sensitive disease rate in postmenopausal patients with estrogen receptor-rich/ERBB2-negative breast cancer receiving neoadjuvant anastrozole, fulvestrant, or their combination: a phase 3 randomized clinical trial

10.1001/jamaoncol.2023.6038 · 2024 · External reference

Molecular characterisation of the residual disease after neoadjuvant endocrine therapy in ER+/HER2-breast cancer uncovers biomarkers of tumour response

10.1016/j.tranon.2025.102407 · 2025 · External reference

Single-cell transcriptomics reveals multi-step adaptations to endocrine therapy

10.1038/s41467-019-11721-9 · 2019 · External reference

Dormant, quiescent, tolerant and persister cells: four synonyms for the same target in cancer

10.1016/j.bcp.2018.11.004 · 2019 · External reference

Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence

10.1038/s41467-022-32523-6 · 2022 · External reference

Elevated GRHL2 imparts plasticity in ER-positive breast cancer cells

10.3390/cancers16162906 · 2024 · External reference

Oxidative phosphorylation is a metabolic vulnerability of endocrine therapy and palbociclib resistant metastatic breast cancers

10.1038/s41467-023-40022-5 · 2023 · External reference

ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer

10.1038/s43018-024-00898-8 · 2025 · External reference

Targeting c-Jun inhibits fatty acid oxidation to overcome tamoxifen resistance in estrogen receptor-positive breast cancer

10.1038/s41419-023-06181-5 · 2023 · External reference

Fatty acid oxidation and autophagy promote endoxifen resistance and counter the effect of AKT inhibition in ER-positive breast cancer cells

10.1093/jmcb/mjab018 · 2021 · External reference

FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation

10.3389/fonc.2023.1105117 · 2023 · External reference

Tafazzin mediates tamoxifen resistance by regulating cellular phospholipid composition in ER-positive breast cancer

10.1038/s41417-023-00683-2 · 2024 · External reference

ZMIZ1 lactylation induces tamoxifen resistance in breast cancer through increasing transcriptional activity of Nanog to impact cell stemness and cholesterol uptake

10.1007/s10565-025-10068-w · 2025 · External reference

Adipocyte-derived extracellular vesicles sustain mitochondrial metabolism in breast cancer cells: New insights into the cross-talk between cancer cells and the tumor microenvironment

10.3892/ijo.2025.5806 · 2025 · External reference

Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER+ breast cancer

10.1007/s10549-022-06794-y · 2023 · External reference

Fatty acid synthase is a key enabler for endocrine resistance in heregulin-overexpressing luminal B-like breast cancer

10.3390/ijms21207661 · 2020 · External reference

Lipid metabolism in breast cancer: From basic research to clinical application

10.3390/cancers17040650 · 2025 · External reference

AP1S3 affects lipid metabolism in breast cancer cells by regulating the PI3K/AKT/mTOR pathway

10.1016/j.bbrc.2025.152200 · 2025 · External reference

Lipid metabolism and resistance to anticancer treatment

10.3390/biology9120474 · 2020 · External reference

Cholesterol-induced metabolic reprogramming in breast cancer cells is mediated via the ERRα pathway

10.3390/cancers13112605 · 2021 · External reference

Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer

10.1186/s13058-016-0713-5 · 2016 · External reference

Metabolism and immunity in breast cancer

10.1007/s11684-020-0793-6 · 2021 · External reference

Metabolic heterogeneity and immunocompetence of infiltrating immune cells in the breast cancer microenvironment (Review)

10.3892/or.2021.7946 · 2021 · External reference

Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling

10.18632/oncotarget.8798 · 2016 · External reference

Prolonged estrogen deprivation triggers a broad immunosuppressive phenotype in breast cancer cells

10.1002/1878-0261.13083 · 2022 · External reference

MHC-I upregulation by macbecin II in the solid tumors potentiates the effect of active immunotherapy

10.1038/s44321-025-00213-7 · 2025 · External reference

MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation

10.1172/jci140837 · 2021 · External reference

Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer

10.1186/s13046-019-1040-3 · 2019 · External reference

Key regulators of lipid metabolism drive endocrine resistance in invasive lobular breast cancer

10.1186/s13058-018-1041-8 · 2018 · External reference

Mogat1 drives metabolic adaptations to evade immune surveillance

10.1038/s41467-025-62134-w · 2025 · External reference

The impact of lipids on the cancer-immunity cycle and strategies for modulating lipid metabolism to improve cancer immunotherapy

10.1016/j.apsb.2022.10.027 · 2023 · External reference

Endocytosis of MHC molecules by distinct membrane rafts

10.1242/jcs.039727 · 2009 · External reference

Docosahexaenoic acid modifies the clustering and size of lipid rafts and the lateral organization and surface expression of MHC class I of EL4 cells

10.3945/jn.109.108720 · 2009 · External reference

Docosahexaenoic acid monoglyceride induces apoptosis and autophagy in breast cancer cells via lipid peroxidation-mediated endoplasmic reticulum stress

10.1111/1750-3841.15900 · 2021 · External reference

ER stress affects processing of MHC class I-associated peptides

10.1186/1471-2172-10-10 · 2009 · External reference

Regulation of lipid metabolism by the unfolded protein response

10.1111/jcmm.16255 · 2021 · External reference

Estrogen receptor signaling drives immune evasion and immunotherapy resistance in HR+ breast cancer

10.1172/jci193153 · 2025 · External reference

SREBP-regulated lipid metabolism: convergent physiology-divergent pathophysiology

10.1038/nrendo.2017.91 · 2017 · External reference

Endoplasmic reticulum stress protein GRP78 modulates lipid metabolism to control drug sensitivity and antitumor immunity in breast cancer

10.1158/0008-5472.can-15-2616 · 2016 · External reference

Lipid metabolism involved in progression and drug resistance of breast cancer

10.1016/j.gendis.2024.101376 · 2024 · External reference

Fatty acid metabolism: A new perspective in breast cancer precision therapy

10.31083/j.fbl2812348 · 2023 · External reference

The multifaceted roles of fatty acid synthesis in cancer

10.1038/nrc.2016.89 · 2016 · External reference

The impact of lipid metabolism on breast cancer: a review about its role in tumorigenesis and immune escape

10.1186/s12964-023-01178-1 · 2023 · External reference

Immunometabolic rewiring in tumorigenesis and anti-tumor immunotherapy

10.1186/s12943-021-01486-5 · 2022 · External reference

Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer

10.1172/jci.insight.138581 · 2020 · External reference

Targeting SCD triggers lipotoxicity of cancer cells and enhances anti-tumor immunity in breast cancer brain metastasis mouse models

10.1038/s42003-025-07977-1 · 2025 · External reference

Lipid accumulation and dendritic cell dysfunction in cancer

10.1038/nm.2172 · 2010 · External reference

ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis

10.1016/j.cell.2015.05.025 · 2015 · External reference

Mesothelioma tumor cells modulate dendritic cell lipid content, phenotype and function

10.1371/journal.pone.0123563 · 2015 · External reference

PPARα inhibition overcomes tumor-derived exosomal lipid-induced dendritic cell dysfunction

10.1016/j.celrep.2020.108278 · 2020 · External reference

Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer

10.1038/s41467-017-02186-9 · 2017 · External reference

Oxidized lipids block antigen cross-presentation by dendritic cells in cancer

10.4049/jimmunol.1302801 · 2014 · External reference

Lipid accumulation in peripheral blood dendritic cells and anticancer immunity in patients with lung cancer

10.1155/2018/5708239 · 2018 · External reference

Intercellular communication between extracellular vesicles from conditioned macrophages and breast cancer cells drives endocrine therapy resistance

10.3389/fcell.2025.1548724 · 2025 · External reference

Expression of adipocyte/macrophage fatty acid-binding protein in tumor-associated macrophages promotes breast cancer progression

10.1158/0008-5472.can-17-2465 · 2018 · External reference

Lipid-associated macrophages in the tumor-adipose microenvironment facilitate breast cancer progression

10.1080/2162402x.2022.2085432 · 2022 · External reference

Targeting tumor-associated macrophages for cancer treatment

10.1186/s13578-022-00823-5 · 2022 · External reference

Bidirectional regulation in the tumour microenvironment: The interaction between tumour-associated macrophages and T cells reshapes the paradigm of cancer immunotherapy

10.1111/imm.70103 · 2026 · External reference

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells

10.1016/j.ccell.2014.09.006 · 2014 · External reference

Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway

10.1007/s12032-014-0352-6 · 2015 · External reference

Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes

10.1158/0008-5472.can-09-4672 · 2010 · External reference

Neutral ceramidase regulates breast cancer progression by metabolic programming of TREM2-associated macrophages

10.1038/s41467-024-45084-7 · 2024 · External reference

Antigen presentation by tumor-associated macrophages drives T cells from a progenitor exhaustion state to terminal exhaustion

10.1016/j.immuni.2024.11.026 · 2025 · External reference

Regulation of CD8+ T cells by lipid metabolism in cancer progression

10.1038/s41423-024-01224-z · 2024 · External reference

Progesterone receptor-dependent downregulation of MHC class I promotes tumor immune evasion and growth in breast cancer

10.1136/jitc-2024-010179 · 2025 · External reference

CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor

10.1016/j.immuni.2022.12.002 · 2023 · External reference

Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment

10.1038/s43018-023-00527-w · 2023 · External reference

The immune microenvironment characterisation and dynamics in hormone receptor-positive breast cancer before and after neoadjuvant endocrine therapy

10.1002/cam4.6425 · 2023 · External reference

Treg control of CD80/CD86 expression mediates immune system homeostasis

10.1002/eji.202551771 · 2025 · External reference

The activation of PPARγ enhances Treg responses through up-regulating CD36/CPT1-mediated fatty acid oxidation and subsequent N-glycan branching of TβRII/IL-2Rα

10.1186/s12964-022-00849-9 · 2022 · External reference

FOXP3 transcriptionally activates fatty acid scavenger receptor CD36 in tumour-induced Treg cells

10.1111/imm.13887 · 2025 · External reference

Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome

10.1158/0008-5472.can-08-2360 · 2009 · External reference

Treg-expressed CTLA-4 depletes CD80/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells

10.1073/pnas.2023739118 · 2021 · External reference

CTLA-4 positive breast cancer cells suppress dendritic cells maturation and function

10.18632/oncotarget.14626 · 2017 · External reference

Boosting immunotherapy efficacy: Empowering the potency of dendritic cells loaded with breast cancer lysates through CTLA-4 suppression

10.1016/j.heliyon.2024.e37699 · 2024 · External reference

Tumor-derived CD4+CD25+regulatory T cells inhibit dendritic cells function by CTLA-4

10.1016/j.prp.2016.12.008 · 2017 · External reference

Lipid metabolic reprogramming in the tumor microenvironment and its mechanistic role in immunosuppressive cells

10.3389/fimmu.2025.1728354 · 2025 · External reference

A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer

10.1038/s41467-022-35238-w · 2023 · External reference

CD8+ T cells in breast cancer tumors and draining lymph nodes: PD-1 levels, effector functions and prognostic relevance

10.1080/2162402x.2025.2502354 · 2025 · External reference

Hallmarks of CD8+ T cell dysfunction are established within hours of tumor antigen encounter before cell division

10.1038/s41590-023-01578-y · 2023 · External reference

Antitumor progenitor exhausted CD8+ T cells are sustained by TCR engagement

10.1038/s41590-024-01843-8 · 2024 · External reference

The cell cycle regulator p16 promotes tumor infiltrated CD8+ T cell exhaustion and apoptosis

10.1038/s41419-024-06721-7 · 2024 · External reference

Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses

10.1136/jitc-2022-006019 · 2023 · External reference

Tumor-associated macrophages expressing the transcription factor IRF8 promote T cell exhaustion in cancer

10.1016/j.immuni.2022.10.002 · 2022 · External reference

Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment

10.1038/s43018-024-00775-4 · 2024 · External reference

PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis

10.1016/j.immuni.2024.08.003 · 2024 · External reference

Acetyl-CoA carboxylase obstructs CD8+ T cell lipid utilization in the tumor microenvironment

10.1016/j.cmet.2024.02.009 · 2024 · External reference

Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer

10.1186/s12943-024-02165-x · 2024 · External reference

Targeting metabolism of breast cancer and its implications in T cell immunotherapy

10.3389/fimmu.2024.1381970 · 2024 · External reference

Resonance of fatty acid metabolism and immune infiltration in anti-PD-1 monotherapy for breast cancer

10.1016/j.tranon.2024.101960 · 2024 · External reference

Circular RNAs as central regulators of metabolic reprogramming and immune responses in the breast cancer microenvironment: A comprehensive review

10.1016/j.biopha.2025.118682 · 2025 · External reference

Targeting the tripartite axis of immune-metabolic-spatial crosstalk to overcome therapy resistance in breast cancer

10.3389/fimmu.2026.1748257 · 2026 · External reference

Fatty acid synthase (FASN) is a tumor-cell-intrinsic metabolic checkpoint restricting T-cell immunity

10.1038/s41420-024-02184-z · 2024 · External reference

FASN inhibits ferroptosis in breast cancer via USP5 palmitoylation-dependent regulation of GPX4 deubiquitination

10.1186/s13046-025-03548-8 · 2025 · External reference

Impact of statin use on breast cancer recurrence and mortality before and after diagnosis: a systematic review and meta-analysis

10.3389/fonc.2023.1256747 · 2023 · External reference

Post-surgery statin use contributes to favorable outcomes in patients with early breast cancer

10.1016/j.canep.2024.102573 · 2024 · External reference

Atorvastatin enhances the efficacy of immune checkpoint therapy and suppresses the cellular and extracellular vesicle PD-L1

10.3390/pharmaceutics14081660 · 2022 · External reference

Statins inhibit paclitaxel-induced PD-L1 expression and increase CD8+ T cytotoxicity for better prognosis in breast cancer

10.1097/js9.0000000000001582 · 2024 · External reference

Targeting metabolism to improve the tumor microenvironment for cancer immunotherapy

10.1016/j.molcel.2020.05.034 · 2020 · External reference

Unlocking the potential of immune checkpoint inhibitors in HR+/HER2- breast cancer: a systematic review

10.3390/cancers17172940 · 2025 · External reference

T cell exclusion, immune privilege, and the tumor microenvironment

10.1126/science.aaa6204 · 2015 · External reference

A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2+ER- breast cancer

10.1038/s41523-025-00742-x · 2025 · External reference

Alteration of the tumor microenvironment with intratumoral dendritic cells before chemotherapy in ERBB2 breast cancer: a nonrandomized clinical trial

10.1001/jamaoncol.2024.5371 · 2025 · External reference

A phase I/II trial of HER2 vaccine-primed autologous T-cell infusions in patients with treatment refractory HER2-overexpressing breast cancer

10.1158/1078-0432.ccr-22-3578 · 2023 · External reference

WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, Malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome

10.1186/s13045-025-01661-x · 2025 · External reference

STING licensing of type I dendritic cells potentiates antitumor immunity

10.1126/sciimmunol.adj3945 · 2024 · External reference

Clinical applications of STING agonists in cancer immunotherapy: current progress and future prospects

10.3389/fimmu.2024.1485546 · 2024 · External reference

Phase II study combining pembrolizumab with aromatase inhibitor in patients with metastatic hormone receptor positive breast cancer

10.3390/cancers14174279 · 2022 · External reference

Hormone therapy enhances anti-PD1 efficacy in premenopausal estrogen receptor-positive and HER2-negative advanced breast cancer

10.1016/j.xcrm.2024.101879 · 2025 · External reference

Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial

10.1038/s41591-024-03414-8 · 2025 · External reference

Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study

10.1038/s41523-022-00482-2 · 2022 · External reference

Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial

10.1038/s43018-024-00729-w · 2024 · External reference

Therapeutic targeting of circTNK2 with nanoparticles restores tamoxifen sensitivity and enhances NK cell-mediated immunity in ER-positive breast cancer

10.1016/j.canlet.2025.217823 · 2025 · External reference

Reprogramming innate immunity to overcome endocrine resistance in estrogen receptor-positive breast cancer

10.1002/ijc.70421 · 2026 · External reference

Inverse FASN and LDHA correlation drives metabolic resistance in breast cancer

10.1186/s12967-024-05517-9 · 2024 · External reference

Metabolic-immuno-hormonal cross-talk in breast cancer: a UAE-based multi-omics perspective

10.1021/acs.jproteome.5c00669 · 2026 · External reference

Biomarker prediction of immunotherapy response in breast cancer: from single markers to multi-omics integration

10.1038/s41523-025-00873-1 · 2025 · External reference

MAP3K1 mutations confer tumor immune heterogeneity in hormone receptor-positive HER2-negative breast cancer

10.1172/jci183656 · 2024 · External reference

A lipid metabolism-related gene signature predicts prognosis after tamoxifen treatment in ER+ breast cancer and reflects tumor microenvironment heterogeneity through single-cell analysis

10.1186/s12920-025-02194-5 · 2025 · External reference

Lipid metabolism in cancer stem cells: reprogramming, mechanisms, crosstalk, and therapeutic approaches

10.1007/s13402-025-01081-6 · 2025 · External reference

Metabolic reprogramming in breast cancer: pathways driving progression, drug resistance, and emerging therapeutics

10.1016/j.bbcan.2025.189396 · 2025 · External reference

ESR1-activating mutations confer metabolic vulnerabilities in ER+ breast cancer

10.1158/0008-5472.can-25-1339 · 2026 · External reference

Metabolic abnormalities and survival among patients with non-metastatic breast cancer

10.1186/s12885-022-10430-9 · 2022 · External reference

A single-cell network approach to decode metabolic regulation in gynecologic and breast cancers

10.1038/s41540-025-00506-0 · 2025 · External reference

Integration of transcriptomics and machine learning for insights into breast cancer: exploring lipid metabolism and immune interactions

10.3389/fimmu.2024.1470167 · 2024 · External reference